Skip to main content

H.R. 4876

Referred to Committee

Medicare Prescription Drug Abuse Prevention Act of 2016

Introduced 3/23/2016•114th Congress•House

Latest Action

Referred to the Subcommittee on Health.

3/29/2016 • House

Summary

Medicare Prescription Drug Abuse Prevention Act of 2016

This bill amends title XVIII (Medicare) of the Social Security Act to: (1) authorize a Medicare prescription drug plan (PDP) sponsor to establish a drug management program under which the PDP sponsor may limit an at-risk beneficiary's access to coverage for frequently abused drugs to include only those drugs that are prescribed by selected prescribers and dispensed by selected pharmacies; and (2) require a PDP sponsor to have in place a utilization management tool to prevent drug abuse.

With respect to a drug management program, a PDP sponsor must: (1) provide specified notice to a beneficiary who has been identified by the Centers for Medicare & Medicaid (CMS) as "at-risk" and consequently enrolled in the program; and (2) in selecting prescribers and dispensers, ensure that the beneficiary continues to have reasonable access to drugs. These determinations shall be subject to expedited reconsideration and appeal. A PDP sponsor must review and consider an at-risk beneficiary's preferences regarding prescriber and pharmacy selection.

Certain individuals, including those receiving hospice care or residing in a long-term care facility, are exempted from enrollment in a drug management program.

CMS must, for purposes of quality or performance assessments, review and consider complaints received from at-risk beneficiaries regarding lack of access due to their enrollment in a drug management program. In addition, CMS must establish rules and procedures requiring a PDP sponsor to provide specified program data.

Introduced in House • 3/23/2016

Enter your district to see how this bill affects your community
-

Topics & Subjects

Policy Area: Health
Administrative law and regulatory proceduresCongressional oversightConsumer affairsDepartment of Health and Human ServicesDrug trafficking and controlled substancesDrug, alcohol, tobacco useFraud offenses and financial crimesGovernment studies and investigationsHealth care coverage and accessHealth information and medical recordsHealth technology, devices, suppliesMedicarePerformance measurementPrescription drugs

Congressional Votes (0)

No recorded votes yet

Roll call votes will appear here as the bill moves through Congress

Related Federal Spending

Sponsor & Cosponsors (4)

Party Breakdown

1
Democrats
3
Republicans
0
Independents

Sponsor

R[
Rep. Meehan, Patrick [R-PA-7]

Republican • PA-7

Sponsored 3/23/2016

Cosponsors (3)

R[
Rep. Neal, Richard E. [D-MA-1]

D-MA-1

Joined 3/23/2016

R[
Rep. Reed, Tom [R-NY-23]

R-NY-23

Joined 4/12/2016

R[
Rep. Tiberi, Patrick J. [R-OH-12]

R-OH-12

Joined 4/27/2016

Bill Journey

Originated in the House

Introduced

March 23, 2016

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Committee Review

Floor Debate

Passed Chamber

Other Chamber

President

Enacted into Law

Text Versions (1)

Introduced in House3/23/2016

Details

Bill TypeHR
Current StatusReferred to Committee
Cosponsors3